Second-Source GMP Drug Substance Supply for a Systemically Administered AAV Gene Therapy: Scientific, Quality, and Regulatory Rationale for a Technology Transfer Campaign
Adeno-associated virus (AAV) vectors have made systemic gene replacement feasible for diseases of muscle and other tissues, but the doses required, commonly in the range of 10 to the power of 13 to 10 to the power of 14 vector genomes per kilogram, convert every patient into a manufacturing problem. This article develops the scientific, quality, and regulatory rationale for qualifying a second drug substance manufacturing site for a hypothetical licensed, systemically administered AAV gene therapy produced by transient transfection of suspension HEK293 cells. It reviews why the payload problem led to engineered transgenes, how AAV manufacturing science defines the critical quality attributes that govern a site transfer (full-to-empty capsid ratio, residual nucleic acids, potency), and what ICH Q5E, FDA comparability guidance, and 21 C.F.R. 601.12 require of a manufacturing change to a licensed biologic. Four alternatives are compared, and a technology transfer with three conformance lots is shown to be the proportionate next step. A companion article converts this rationale into a request for proposal.Keywords: AAV gene therapy; drug substance; second-source manufacturing; comparability; ICH Q5E; potency assurance; capsid quality
Authors
- Kishan Rajput
- Peivand Pirouzi
- Pruthvirajsinh Sindha
- Sukhpreet Singh Maan
- Vraj Modi
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24425187
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00